Retatrutide in Connecticut: Trial-registry Status and Research Records

At a glance

• Review question / What do federal sources and ClinicalTrials.gov records establish about retatrutide in Connecticut?
• Best evidence / federal status and trial-registry records
• Evidence snapshot / 2026-08-09
• Commercial status / no FDA-approved product or ordinary retail supply
• HealthRX role / independent educational review; no retatrutide product or treatment offer

Direct answer

Retatrutide is not commercially available in the state. In the 2026-08-09 ClinicalTrials.gov snapshot, 8 retatrutide study records listed at least one location in Connecticut. Example identifiers were NCT05882045, NCT05929066, NCT05929079. A location listing can describe a completed, active, or planned site; it does not establish current recruitment, eligibility, public supply, or commercial availability.

The wording here is deliberately evidence-specific. “A study exists,” “a registry lists a site,” and “a paper reports an endpoint” are different statements from “a product is approved,” “a treatment works,” or “a person should use it.” This page makes only the first type of statement and links the controlling source.

Evidence map for trial-registry status in Connecticut

How HealthRX evaluated this question

ClinicalTrials.gov is a registry, not a pharmacy directory. Location modules can include sites for completed, active, or planned studies and can change after a record is posted. HealthRX reviewed the registry-level state field, record identifier, and snapshot date—not private eligibility information or unverified third-party trial listings.

For this page, HealthRX asked: (1) Is trial-registry status in Connecticut named in the protocol or publication? (2) Was it a prespecified endpoint, eligibility factor, subgroup, or only background context? (3) Is the record complete, current, and peer reviewed? (4) Does an FDA action or approved label exist? That sequence prevents a research observation from being rewritten as a product claim.

Evidence checks specific to this record

Endpoint definition

Use the protocol's exact definition, unit, assessment method, and analysis time. Similar-sounding endpoints can measure different constructs. For trial-registry status in Connecticut, a change in wording, threshold, or time point may materially change the research question.

Registry-to-publication match

Match the publication to its registry identifier, enrolled population, protocol version, and prespecified outcomes. If trial-registry status in Connecticut appears in a paper but not in the registered plan, readers should determine whether it was added, redefined, or reported as an exploratory analysis.

Replication threshold

One record can establish that a question was studied. Confidence in trial-registry status in Connecticut grows when methods and findings are reproduced in an appropriate population, reported completely, and reconciled with the broader evidence base. Replication is different from repetition of the same dataset.

Subgroup stability

A subgroup result needs adequate representation, a prespecified interaction test, transparent multiplicity handling, and consistency across relevant analyses. Merely listing a demographic or clinical subgroup does not establish a subgroup-specific conclusion about trial-registry status in Connecticut.

Question-to-source fit

Use the source that can actually answer the question. FDA records control regulatory status, registries document study plans, protocols define methods, and publications report analyses. For trial-registry status in Connecticut, a lower-level source should not be used to make a higher-level claim.

What remains unresolved

Federal approval and compounding status do not change by state. A Connecticut location in a study record is research metadata, not a retail listing, prescription pathway, price, insurance benefit, or HealthRX offering.

The source hierarchy also matters. An FDA action controls approval status. ClinicalTrials.gov controls the public registry record. A peer-reviewed report can describe study methods and observations. A press release, seller page, social post, search result, or anecdote cannot replace those sources.

What evidence could change the answer

Readers evaluating a registry record should check its current overall status, site status, eligibility criteria, last update date, sponsor, and official contact fields directly on ClinicalTrials.gov.

Any new result should be read with its protocol and statistical analysis plan. Important checks include enrollment, prespecified outcomes, follow-up duration, missing-data handling, multiplicity, participant flow, sponsor involvement, and whether the finding has undergone peer review and regulatory review.

Current federal and commercial status

Retatrutide remains investigational. No retatrutide product is FDA-approved for any indication or available through ordinary commercial prescription or retail sale. FDA states that retatrutide cannot be used in compounding under federal law. HealthRX does not offer it. FDA's current statement says retatrutide is not a component of an FDA-approved drug and cannot be used in compounding under federal law. A ClinicalTrials.gov study or eligibility-limited expanded-access record is not commercial approval, ordinary prescribing, retail availability, or evidence that HealthRX offers the investigational substance.

Federal regulation distinguishes scientific exchange from promotion: it does not restrict full exchange of scientific information, but it does restrict representing an investigational drug as safe or effective in a promotional context and precludes commercialization before approval.

Source selection and review method

HealthRX reviewed primary or primary-index sources current to 2026-08-09: ClinicalTrials.gov record NCT05929066; ClinicalTrials.gov record NCT04881760; ClinicalTrials.gov pre-approval expanded-access record NCT07629401; FDA status statement for unapproved GLP-1 drugs; 21 CFR 312.7, Promotion of investigational drugs. Sources were selected because they control regulatory status, register a study, or index a peer-reviewed clinical report. The review reports study design and evidence limits without reproducing promotional outcome claims or converting protocols into patient instructions.

Frequently asked questions

›Does a study location mean retatrutide is available for prescription?

No. A ClinicalTrials.gov location is research metadata. It does not establish commercial supply, ordinary prescribing, pharmacy dispensing, insurance coverage, or eligibility for a study.

›Can state law make compounded retatrutide permissible?

FDA states that retatrutide cannot be used in compounding under federal law. A state location does not change that federal status.

›How current is the trial-registry status in Connecticut review?

HealthRX checked FDA, federal-regulation, publication, and ClinicalTrials.gov records on 2026-08-09. Registry locations and study statuses can change, so the linked primary record controls.

References

1. ClinicalTrials.gov. TRIUMPH-1 registry record. 2026. https://clinicaltrials.gov/study/NCT05929066
2. ClinicalTrials.gov. Phase 2 obesity-study registry record. 2026. https://clinicaltrials.gov/study/NCT04881760
3. ClinicalTrials.gov. Pre-approval expanded-access registry record. 2026. https://clinicaltrials.gov/study/NCT07629401
4. U.S. Food and Drug Administration. FDA status statement for unapproved GLP-1 drugs. 2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
5. Electronic Code of Federal Regulations. 21 CFR 312.7, Promotion of investigational drugs. 2026. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-312/subpart-A/section-312.7